Cadonilimab is a PD-1/CTLA-4 bispecific monoclonal antibody developed to treat a variety of solid cancer types. In June, 2022 it was approved in China "for use in…
Cadonilimab is a PD-1/CTLA-4 bispecific monoclonal antibody developed to treat a variety of solid cancer types. In June, 2022 it was approved in China "for use in patients with relapsed or metastatic cervical cancer (r/mCC) who have progressed on or after platinum-based chemotherapy".
References
Gebaseerd op: Wikipedia — Cadonilimab · auteursgeschiedenis.
Tekst: CC BY-SA 4.0.
Wikisyntaxis en sjablonen zijn verwijderd; langere teksten zijn ingekort.